Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Prednisone”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 811 records · Page 45Linked to original sources

Hepatic total 3 alpha-hydroxy bile acids concentration and enzyme activities in prednisone-treated dogs.

High serum alkaline phosphatase (ALP) activity is considered a sensitive marker of cholestasis in most mammalian species, including dogs. Induction of high serum ALP activity in association with cholestasis is dependent on high hepatic bile acids concentrations. Treatment of dogs with glucocorticoids also results in high serum ALP activity. The possible causal relation between serum ALP activity and bile acids concentration was investigated in dogs treated with glucocorticoids. The relation of glucocorticoid treatment to changes in the activity of individual ALP isoenzymes, alanine transaminase (ALT) and gamma-glutamyltransferase (GGT) also was investigated. Eight conditioned dogs were given 4 mg of prednisone/kg of body weight, i.m., daily for 10 days. Blood samples were taken prior to treatment and on treatment days 3, 5, 7, and 10. Liver tissue was then taken from each dog. Serum total ALP activity was significantly (P < 0.05) high at day 3 in prednisone-treated dogs. Isoenzyme analysis indicated that this increase was attributable to an increase in the liver ALP isoenzyme (LALP). Significant increases in serum corticosteroid-induced ALP (CALP) and bone ALP were first observed on days 7 and 10, respectively. Serum ALT and GGT activities were significantly increased by day 5. Increased serum or hepatic tissue bile acids concentrations were not observed in prednisone-treated dogs, compared with values in 8 clinically normal (control) dogs, but were high in 3 dogs with complete bile duct ligation. Hepatic activities of LALP, CALP, and GGT were higher in prednisone-treated dogs than values in controls, indicating probable increased hepatic synthesis of these enzymes. Hepatic ALT activity was not increased.(ABSTRACT TRUNCATED AT 250 WORDS)

Alanine Transaminase↗

Long-term therapy with the new glucocorticosteroid deflazacort in rheumatoid arthritis. Double-blind controlled randomized 12-months study against prednisone.

The long-term anti-inflammatory and immunosuppressive properties and the safety of deflazacort (Calcort, CAS 14484-47-0) were assessed investigating the effect on clinical symptoms and safety parameters in patients with rheumatoid arthritis compared to prednisone as standard therapy in a randomized double-blind controlled clinical trial. Monitoring was performed according to GCP-guidelines closely in order to have a maximum of the patients entered completed at the end of the 12-month therapy with high data quality. 76 patients, meeting the criteria for classical or definite rheumatoid arthritis and requiring corticosteroid therapy, were randomly allocated to a 12-months treatment with either deflazacort (6 mg/tablet) or the corticoid standard prednisone (5 mg/tablet). Steady state dosage between 1/2 and 3 tablets per day was individually adjusted according to the severity of the clinical symptoms. Due to the close monitoring of the trial in the 6 study centres, 25 patients completed 12 months of deflazacort and 28 patients 12 months of prednisone treatment, being controlled 7 times during the trial. Five efficacy parameters were assessed at each visit: Ritchie Index, duration of morning stiffness, grip strength, effective dosage of study medication and global assessment of disease status. Following safety and tolerance parameters were controlled during the trial: vital signs, weight, Cushing's symptoms and adverse events at each visit; 32 laboratory parameters at 6 visits; ECG at 3 visits; and the global tolerance was assessed at the end of the study.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis.

The aim of this investigation was to compare inhaled budesonide with oral prednisone in maintenance treatment of pulmonary sarcoidosis. A double-blind controlled study was performed in 40 patients with stage II or III pulmonary sarcoidosis. After initial systemic 6 weeks treatment with prednisone (40 reduced to 20 mg daily) patients were allocated either to the systematically (S) or topically (T) treated group. S patients continued with 10 mg prednisone daily, T patients were given inhaled budesonide 1.6 mg daily. The progress of treatment was assessed by serial radiography, spirometry, serum Angiotensin Converting Enzyme (ACE) activity and plasma cortisol levels. All patients completed the 12 months treatment. Using the numerical score to assess changes on the chest radiograms S patients improved by 1.7 +/- 0.66 points; T patients improved by 1.15 +/- 0.81 points. Spirometric changes were not statistically significant. Serum ACE fell from 107 +/- 51 U/L in the S group and 92 +/- 40 U/L in the T group to 46 +/- 11 U/L and 38 +/- 21 U/L respectively during the initial phase of treatment. In the maintenance phase ACE levels remained lower than the initial ones in both groups. Morning plasma cortisol levels studied in 10 patients (5 in each group) decreased significantly during the initial phase. Thereafter cortisol levels remained low in the S patients returning to the lower limit of normal values in the T patients. We conclude that inhaled budesonide may be a safe and effective alternative to oral steroids in the maintenance treatment of pulmonary sarcoidosis especially in the early stage of the disease.

Administration, Inhalation↗

Treatment of refractory Evans syndrome with alternate-day cyclosporine and prednisone.

PURPOSE: We report that the use of alternate-day cyclosporine and prednisone improved the clinical course of a 6-year-old child with severe Evans syndrome. Before the use of cyclosporine the child had experienced life-threatening episodes of hemolytic anemia despite the use of multiple therapeutic modalities. METHODS: Cyclosporine was given at a dose of 10 mg/kg/day divided into two doses on alternate days. RESULTS: The use of cyclosporine resulted in increased hemoglobin levels, increased platelet counts, and the reduction of the patient's prednisone dose from 2 mg/kg/day to as low as 1 mg/kg every other day. With this regimen, the patient had less severe hemolytic anemia, was less thrombocytopenic, and had fewer hospitalizations. No major toxic effects were associated with cyclosporine therapy. CONCLUSION: The regimen of alternate-day cyclosporine and prednisone may prove to be useful in the treatment of other patients with refractory Evans syndrome.

Anemia, Hemolytic, Autoimmune↗

Collaborative study of a semiautomated method for the analysis of prednisolone and prednisone tablets.

A semiautomated colorimetric method for the determination of prednisolone and prednisone was collaboratively studied by 6 collaborators. In the method, an alcoholic solution of the drug is extracted with chloroform and the extract is reacted with tetramethylammonium hydroxide and blue tetrazolium; the absorbance of the resulting color is read at 525 nm. Collaborators were supplied with 4 composites of tablets of different dosage levels, 2 containing prednisolone and 2 containing prednisone. Results agreed with those obtained by the author using the USP total steroid assay method. The coefficients of variation of the individual collaborator's results for prednisolone and prednisone ranged from 0.54 to 2.38 and from 0.34 to 2.19%, respectively. This method has been adopted as official first action.

Autoanalysis↗

Deflazacort in the treatment of uveitis: a comparative study versus prednisone.

Since corticosteroids represent a fundamental tool in the treatment of uveitis, we evaluate the clinical efficacy and possible appearance of side effects of deflazacort, a new corticosteroid of third generation, versus prednisone at equiactive dosages. Sixty six patients suffering from recurring acute anterior uveitis (RAAU) and/or chronic anterior uveitis (CAU) were treated with deflazacort or alternatively prednisone in an "open" study. Clinical efficacy, ophthalmological parameters and haemato-bioassays were evaluated on admission and during the treatment period. All patients showed a complete remission of clinical signs and symptoms with both treatment and no statistically significant difference was evidenced between the studied groups. Concerning the possible appearance of side effects, the comparison between deflazacort and prednisone a statistically significant difference. These preliminary results are strongly encouraging and suggest further controlled studies on the employment of deflazacort in the treatment of uveitis.

Acute Disease↗

Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of "Arbetsgemeinschaft für Pädiatrische Nephrologie".

23 children with frequently relapsing minimal-change nephrotic syndrome were treated with alternate-day prednisone (35 mg/m2/48 h) and 25 other patients were treated with intermittent prednisone (40 mg/m2 on three consecutive days out of seven) for six months. This was followed by six months without any maintenance steroid treatment except when relapse required a short period of prednisone therapy until remission. The number of relapsers was significantly lower on alternate-day than on intermittent treatment. In the alternate-day group, the number of relapsers and the rate of relapse was significantly less before treatment withdrawal; in the intermittent group, only the number of relapsers was reduced. An alternate-day regiment is therefore preferable to the intermittent regimen in the interrupted steroid treatment of children with nephrotic syndrome.

Adolescent↗

[Antiphospholipid antibodies in women with habitual abortions. Treatment with prednisone and acetylsalicylic acid during pregnancy].

PURPOSE: To discover the prevalence of antiphospholipid antibodies in women with a history of repeated miscarriages. Therapy evaluation of aspirin and prednisone to achieve living term foetus from women in whom antiphospholipid antibodies had been detected and who had become pregnant again. PATIENTS AND METHODS: 82 consecutive women with history of at least of two miscarriages, with no live foetus in either case. 14 women positive for antiphospholipid antibodies who had become pregnant again (group of therapy evaluation), were treated with aspirin (125 mg/d) and prednisone (20 mg/d). 60 normal pregnant women (control group). Lupus anticoagulant evaluation: APTT tests caolin clotting time and APTT system neutralized with platelet phospholipids. Antiphospholipid antibodies: ELISA test. RESULTS: 13.4% were positive to antiphospholipid antibodies (ELISA), and 2.4% were positive in both positive in both test. Therapy evaluation: 75.5% (11 cases) of pregnancies were successful (normal foetus), 14% (2 cases) of fetal losses, and 7% (1 case) of foetal malformations (acranius). CONCLUSIONS: In our study the antiphospholipid antibodies represent one of the main causes of repeated foetal losses. We recommended in cases of infertile women to test for antiphospholipid antibodies regularly. We confirm the effectiveness of the therapy (aspirin and prednisone) in achieving successful pregnancies in patients with a history of infertility.

Abortion, Habitual↗

[Effects of prednisone and azathioprine treatment on oligoclonal IGG in the cerebrospinal fluid of multiple sclerosis patients. Preliminary communication].

The influence of high-dose prednisone and azathioprine therapy on oligoclonal IgG in the CSF of MS patients was studied. The oligoclonal bands were present in 93% of patients treated with prednisone and in 90% of patients treated with azathioprine. After the treatment with prednisone, the oligoclonal bands density was diminished in 3 patients, and after the treatment with azathioprine in 1 patient. The number of bands and their pattern remained the same.

Anti-Inflammatory Agents↗

Long-term effect of interferon alpha alone or after prednisone withdrawal in chronic hepatitis B. Interim report and review of the literature.

BACKGROUND/AIMS: This study analyzed the response of two selected groups of asymptomatic chronic hepatitis B patients, treated either with Interferon or with Prednisone plus the same regimen of Interferon, on finalizing treatment and after a long-term follow-up. PATIENTS AND METHODS: Twelve patients received Interferon over 6 months (group I) and 7 patients Prednisone plus Interferon with the same regimen (group II). Both groups were homogeneous in age, sexual preferences, serum ALT levels, liver histology and Knodell's index. Patients with decompensated liver disease, ongoing drug abuse, active alcoholism or viral superinfections were excluded. RESULTS: On finalizing treatment, no statistical differences were observed in either group, except for clearance of HBsAg, found to be better in group II. Both treatments improved hepatic histology. These results were comparable with those reported for both therapeutical regimens in the literature. After a mean follow-up period of 1.8 years for group I and 3.5 years for group II, no patient included in group II relapsed and 2 additionally cleared their replication markers; thus, a complete response was achieved in 6 (86%) out of 7 patients. In group I, however, 3 patients relapsed and 4 presented no change, obtaining a complete response in 3 (27%) out of 11 followed-up patients. When statistically studied, this improved response in the Prednisone plus Interferon group was significant in clearing HBV DNA, HBeAg and HBsAg and, also, in normalizing ALT levels. CONCLUSIONS: In spite of the few number of cases studied, these results could indicate an improved long-term evolution after a short course of steroids prior to Interferon in selected chronic hepatitis B patients.

Adult↗

[Prednisone therapy in patients with pernicious anemia (report of 2 cases)].

The effects of Prednisone therapy at two patients with pernicious anemia were studied on haematologic response, gastric secretion and gastric mucosal hystology. The treatment resulted in each case in correctin of the megaloblastic to normoblastic erythropoesis, and increse in reticulocytes, hemoglobin level and red cell count. Schilling-s test was normalised in one case that means that Prednison enchanced B12 absorption. Gastric secretion of acid and gastric hystology were not respond during the Prednisone therapy. It was discused about immunological problems in pernicious anemia which are very important and required continued investigations.

Anemia, Pernicious↗

Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis.

OBJECTIVE: Polyamines are increased in activated lymphocytes, including peripheral blood lymphocytes (PBL) from patients with rheumatoid arthritis (RA), and are important in modulating immune-mediated cellular responses. In vitro studies have suggested that methotrexate (MTX) interferes with polyamine synthesis. This study evaluated the in vivo polyamine response to MTX compared to other anti-arthritic agents, and correlated it with the clinical and immunological response. METHODS: The polyamine content of PBL was determined in 14 RA patients at initiation of treatment with MTX (n = 8), hydroxychloroquine (HCQ) (n = 3), or prednisone (n = 3), and then monthly for four months. IgM rheumatoid factor (RF) synthesis by PBL in vitro was assessed and tender joints were counted monthly. RESULTS: Polyamines (spermine and spermidine) decreased by 55% at three months in the MTX group compared to 4% and 9% in the HCQ and prednisone groups, respectively (p < 0.01). However, group differences in the clinical and immunological response were not significant. In the MTX group there was a positive correlation between polyamine levels and the joint count. Such a correlation was not observed in the other groups. CONCLUSION: These data suggest that MTX interference with the polyamine pathway is not shared by prednisone and HCQ, and is associated with its beneficial effect in RA.

Adult↗

Effect of liquid diet on serum protein binding and prednisolone concentrations after oral prednisone.

After prednisone (two 5 mg tablets) was given to each of six normal volunteers with water or with a liquid meal, standard pharmacokinetic parameters of prednisolone metabolism were similar, except that peak serum prednisolone concentrations occurred later after the meal. We conclude that prednisone can be given with a meal without significantly affecting the metabolism of prednisone or prednisolone.

Administration, Oral↗

Is the histamine skin test inhibited by prednisone?

BACKGROUND: A clinical trial was carried out to determine whether therapeutic doses of prednisone could inhibit the response to the histamine skin test. METHODS: Forty-five male and female asthmatic and allergic patients participated in the study, their ages ranged from 6-14 years old (16 girls and 29 boys). The clinical trial was random, double-blind, and placebo-controlled. METHODS: Three treatment groups were formed and patients were assigned randomly to them. Groups A and B received prednisone at 0.5 and 1 mg/kg/day, respectively, whereas group C received a placebo (p.o.). All treatments lasted for 10 days. The histamine test was applied on the first, fifth and tenth days of treatment, and the size of the wheal and the extension of the flare were evaluated 5 min after the application of the test. The statistical tool used was ANOVA, since the study sought to see the difference among the treatment groups, after including 45 patients in three groups of 15 patients each. RESULTS: No significant statistical difference was observed among the groups using an ANOVA test. CONCLUSIONS: It was concluded that the response to the histamine test was not modified by a 10-day treatment with prednisone at doses of 0.5 mg/kg/day and 1 mg/kg/day.

Adolescent↗

Anaphylactic reaction to oral prednisone: a case report and review of the literature.

Reports of corticosteroid anaphylactic reactions are rare in the medical literature. We describe the case of a nonatopic 17-year-old girl with bronchial asthma and aspirin intolerance who developed a dramatic anaphylactic reaction to oral prednisone. She recovered with shock therapy and intravenous administration of diphenhydramine and hydrocortisone. Intradermal testing with a wide range of steroid preparations gave positive results to prednisone. No reactions occurred to methylprednisolone and hydrocortisone. This case and the brief review of the literature which follows emphasize the danger of prednisone administration in patients who have asthma and a history of drug intolerance.

Administration, Oral↗

A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3).

Adult Clinical Trials Group Study 349 examined the immunology, virology, and safety of 40 mg/d prednisone as an adjunct to antiretroviral therapy in 24 HIV-infected subjects with >200 CD4+ T cells/mm in a randomized placebo-controlled trial. After 8 weeks, median lymphocyte and CD4+ cell numbers increased >40% above baseline values (p =.08). No effect was observed on markers of cell activation or apoptosis, although the proportion of CD28+ CD8+ T cells increased (p =.006). Prednisone inhibited monocyte TNFalpha production without affecting T-cell responses to antigens or mitogens. Two subjects assigned to prednisone were subsequently found to have asymptomatic osteonecrosis of the hip. Many questions remain regarding the role of activation-induced sequestration and apoptosis as causes of progressive CD4+ T-cell loss in AIDS. The potential role of corticosteroids as tools to examine this question will be limited by concerns regarding their toxicity; however, further studies of other agents to limit cellular activation in AIDS are warranted.

Adult↗

Reversal of protein losing enteropathy with prednisone in adults with modified fontan operations: long term palliation or bridge to cardiac transplantation?

Protein losing enteropathy (PLE), defined as severe loss of serum protein into the intestine, occurs in 4-13% of patients after the Fontan procedure and carries a dismal prognosis with a five year survival between 46% and 59%. Chronically raised systemic venous pressure is thought to be responsible for the development of PLE in these patients, with perhaps superimposed immunological or inflammatory factors. The success rate of contemporary medical, transcatheter, and surgical treatments attempting to reduce systemic venous pressure ranges from 19% to 40%. Prednisone treatment for PLE has been tried, with variable success rates reported in children. The effect of prednisone in adult patients with PLE after the Fontan procedure is largely unknown. Two cases of PLE in adults (a 39 year old woman and a 25 year old man) after modified Fontan procedure who responded dramatically to oral prednisone treatment are reported, suggesting that a trial of this "non-invasive" treatment should be considered as long term palliation or bridge to cardiac transplantation.

Adult↗

[Idiopathic primary pulmonary hemosiderosis: treatment with cyclophosphamide and prednisone].

The authors present the case of a child diagnosed as having idiopathic pulmonary hemosiderosis at five years of age who had a good clinical outcome at the age of ten years. Initially the patient was treated with prednisone and chloroquine with poor results. When cyclophosphamide was added to prednisone, the patient demonstrated clinical and radiological remission. To date, the patient has been followed for one year without any medication, and has had only one limited episode of hemosiderosis. The authors also suggest that the therapeutic regimen with cyclophosphamide and prednisone may be useful for some selected cases.

English Abstract↗